Home  Welcoming remarks Plenaries & events Panels Advance day Exhibition Benefactors Organizers Info

BioSight Ltd.

BioSight Ltd.

Medical -




BioSight Ltd. is a biopharmaceutical company developing a pipeline

of pro-drug guided vectors that can target and release therapeutic

drugs directly into cancerous tumors, while significantly minimizing

the side effects associated with chemotherapy treatments.

BioSight is located in Karmiel - at the heart of the Galilee area - and is

a “made in Israel” company, with its entrepreneurs, team, intellectual

property, investors, shareholders and government financial support

all coming from Israel.

BioSight’s novel and proprietary drug targeting platform technology

S2DOT (Seek to Destroy Only Target) is applicable to a wide range of

cancer types and designed to:

• Target and release the drug selectively to

cancerous cells

• Significantly minimize side effects arising from

systemic toxicity

• Increase efficacy using increased therapeutic doses.

The company’s intellectual property is a keystone in its corporate

strategy. BioSight has already filed three families of patents, while the

platform technology patent has already been granted.

The company’s lead compound, BST105, has already demonstrated

an exceptional safety profile in toxicological studies and proof of

concept in vitro and in vivo, and aims to begin human clinical trials.

BioSight’s future plans include creating new vectors to target a variety

of acute cancers, identifying new targets for drug discovery and

diagnostics and applying the technology to other areas, including

inflammatory and infectious diseases.

BioSight’s technology is developed with the aim of becoming a major

player in the multibillion-dollar cancer and drug delivery markets.

BioSight’s mission is to carry out the “drug revolution” which will change

the way medicine grapples with cancer.




Watch movie >>

<< Back
Home Plenaries & events Panels Exhibition: “Tomorrow’s Spaces” Benefactors Info & schedule Conference Album Articles
Background Policy Papers prepared for the President's Conference

Powered by HAARETZ